By / September 24, 2020

Cannabis-based products reach Peruvian private market

For the first time ever, medicinal cannabis-based products are marketed through private channels in Peru. The Colombian cannabis company, Khiron Life Sciences, was the first to receive the import license from the General Directorate of Medicines, Supplies and Drugs (DIGEMID), and began the distribution and sale of these products in the country on Monday, September 21.

The general manager of the company, Luis Márquez, explained that the commercialization stage of cannabis-based products can only occur after complying with all the regulatory processes in the country. 

“The coronavirus pandemic began at the worst possible time and of course it has weighed-down considerably the process getting products to market in terms of certain regulatory and import/transport difficulties”, he said.

“But today we already have this product available in two forms”, expressing that even during these difficult times, the company managed to finish its cannabis deal and is now selling these products in Peruvian pharmacies.

If you want to know more about cannabis, how Peru is starting to sell cannabis-based products, how Khirion Life is expanding its operation across Latin America, and to find out the latest cannabis news, download the mobile application.

A variety of cannabis-based products will be distributed across Peru

These products will be available as either 30 milligrams per 30 milliliters of Cannabidiol (CBD) – a non-psychoactive component from cannabis with incredible medical potential – or 100 milligrams per 50 milliliters of Cannabidiol (CBD). As Márquez explained, the use of CBD is effective for a wide number of treatments, like: anxiety, the control of neurological diseases and multiple sclerosis.

Currently, the popularity of cannabis-based products is increasing around the world at an exponential rate, due to the fact that many patients are looking for alternate treatments and are finding that cannabis is a viable and effective option. 

In Peru, Farmacias Universal will be in charge of preparing and organizing all cannabis requests made by patients under specific treatments. Dolores Guevara, general manager of the aforementioned pharmacy, explained how the product will be commercialized and sold in the country.

Cannabis patients will need a certified prescription in order to access these products

“Patients looking for these cannabis-based products should approach with their respective and certified prescription that has been issued by a professional doctor, indicating the types of products needed. We will also verify that the patients are registered with the General Directorate of Medicines, Supplies and Drugs (DIGEMID)”, he explained ensuring that stricts measures will be taken in order to correctly distribute these products.

Khiron Life Science is the first company to market its products in Peru by private channels and it plans to commercialize two more medicinal cannabis-based products in the last quarter of 2020. Furthermore, once it obtains the respective permission from the Minsa, it plans to release natural products for health use on the Peruvian market.

“We realize that, depending on all the pathologies in which medical cannabis could have a place, there are two and a half million Peruvian patients who could benefit from it. Of course, not everyone is a viable candidate, but there are a large number of patients that could benefit from these cannabis products, ” said Khiron’s manager, Luis Márquez.


(Featured image by HempCrew via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in El Comercio, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.